ValiRx plc (AIM:VAL)

Market Cap	1.42M -20.1%
Revenue (ttm)	49.78K +418.5%
Net Income	-1.78M
EPS	-0.01
Shares Out	767.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	428,227
Open	0.1890
Previous Close	0.1850
Day's Range	0.1800 - 0.1900
52-Week Range	0.1700 - 0.8750
Beta	-0.61
Analysts	n/a
Price Target	16,406.25 (+8,703,480.9%)
Earnings Date	May 5, 2026

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 14
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL

Financial Performance

In 2024, ValiRx's revenue was 49,775, an increase of 418.49% compared to the previous year's 9,600. Losses were -1.92 million, -5.99% less than in 2023.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 16, 2026

Data Sources Report a data error